ID
45824
Beskrivning
Principal Investigator: Timothy A. Chan, MD, PhD, Vice Chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA MeSH: Melanoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001038 We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway and re-expression of epigenetically silenced endogenous retrovirus. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
Länk
Nyckelord
Versioner (1)
- 2023-07-11 2023-07-11 - Simon Heim
Rättsinnehavare
Timothy A. Chan, MD, PhD, Vice Chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Uppladdad den
11 juli 2023
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs001038 DNA Methylation Inhibitors in Immunotherapy
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases and case control status of the subject. All subjects are patients with melanoma who were treated with ipilimumab or tremelimumab.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject ID, patient's cohort and age, living status during last assessment, gender, number of prior therapies, clinical benefit, tumor location and largest dimension, biopsy type, primary melanoma type, ipilimumab dose, drug treatment, response duration, serum lactate dehydrogenase, BRAF (GeneID: 673) or NRAS (GeneID: 4893) gene mutations, overall survival, and biopsy status before and after treatment.
- This sample attributes table contains sample ID, body site where tumor sample was collected, analyte type, tumor status, histological type, primary metastatic tumor, tumor stage and treatment, and names of the center which conducted genotyping and sequencing.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases and case control status of the subject. All subjects are patients with melanoma who were treated with ipilimumab or tremelimumab.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject ID, patient's cohort and age, living status during last assessment, gender, number of prior therapies, clinical benefit, tumor location and largest dimension, biopsy type, primary melanoma type, ipilimumab dose, drug treatment, response duration, serum lactate dehydrogenase, BRAF (GeneID: 673) or NRAS (GeneID: 4893) gene mutations, overall survival, and biopsy status before and after treatment.
- This sample attributes table contains sample ID, body site where tumor sample was collected, analyte type, tumor status, histological type, primary metastatic tumor, tumor stage and treatment, and names of the center which conducted genotyping and sequencing.
C0680251 (UMLS CUI [1,2])
C0025202 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C1367202 (UMLS CUI [1,4])
C2351038 (UMLS CUI [1,5])